These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1032 related articles for article (PubMed ID: 25784798)

  • 1. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
    Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
    Liao KM; Lin TY; Huang YB; Kuo CC; Chen CY
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2573-2581. PubMed ID: 28894360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
    Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
    Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
    Su VY; Chang YS; Hu YW; Hung MH; Ou SM; Lee FY; Chou KT; Yang KY; Perng DW; Chen TJ; Liu CJ
    Medicine (Baltimore); 2016 Feb; 95(5):e2427. PubMed ID: 26844454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
    Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure.
    Miró Ò; Müller C; Martín-Sánchez FJ; Bueno H; Mebazaa A; Herrero P; Jacob J; Gil V; Escoda R; Llorens P;
    Clin Res Cardiol; 2016 Dec; 105(12):1021-1029. PubMed ID: 27379611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
    Sessa M; Mascolo A; Mortensen RN; Andersen MP; Rosano GMC; Capuano A; Rossi F; Gislason G; Enghusen-Poulsen H; Torp-Pedersen C
    Eur J Heart Fail; 2018 Mar; 20(3):548-556. PubMed ID: 29159953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
    Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
    Fröhlich H; Torres L; Täger T; Schellberg D; Corletto A; Kazmi S; Goode K; Grundtvig M; Hole T; Katus HA; Cleland JGF; Atar D; Clark AL; Agewall S; Frankenstein L
    Clin Res Cardiol; 2017 Sep; 106(9):711-721. PubMed ID: 28434020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
    Lin TY; Chen CY; Huang YB
    Int J Cardiol; 2017 Mar; 230():378-383. PubMed ID: 28041715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).
    Mentz RJ; Wojdyla D; Fiuzat M; Chiswell K; Fonarow GC; O'Connor CM
    Am J Cardiol; 2013 Feb; 111(4):582-7. PubMed ID: 23200803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of beta-blockers on ventilation efficiency in heart failure.
    Agostoni P; Apostolo A; Cattadori G; Salvioni E; Berna G; Antonioli L; Vignati C; Schina M; Sciomer S; Bussotti M; Palermo P; Fiorentini C; Contini M
    Am Heart J; 2010 Jun; 159(6):1067-73. PubMed ID: 20569721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
    Go AS; Yang J; Gurwitz JH; Hsu J; Lane K; Platt R
    Am J Cardiol; 2007 Aug; 100(4):690-6. PubMed ID: 17697830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
    Galatius S; Gustafsson F; Atar D; Hildebrandt PR
    Cardiology; 2004; 102(3):160-5. PubMed ID: 15334027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?
    Agostoni P; Contini M; Cattadori G; Apostolo A; Sciomer S; Bussotti M; Palermo P; Fiorentini C
    Eur J Heart Fail; 2007 Aug; 9(8):827-33. PubMed ID: 17561440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction.
    Yanagihara K; Kinugasa Y; Sugihara S; Hirai M; Yamada K; Ishida K; Kato M; Yamamoto K
    J Cardiovasc Pharmacol; 2013 Nov; 62(5):485-90. PubMed ID: 24072178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
    Hori M; Nagai R; Izumi T; Matsuzaki M
    Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.